EndocrinologyA Potential Targeting Gene Therapy For Developing HCV
Gene therapy has emerged as a novel approach to combat HCV infection in the last few years. However, one of the most important obstacles to overcome is "targeting": the appropriate genes must be delivered and expressed in HCV infected hepatocytes without harming normal tissues.
A research article published in the World Journal of Gastroenterology addresses this issue. The research team led by Professor Feng from Central South University cloned the 2"-5"oligoadenylate synthetase (OAS) promoter and investigated its activity in the HCV-core positive liver cells. Since the role of HCV-core protein in modulating OAS gene expression is very controversial, this article further investigates the relationship of HCV-core protein and OAS promoter in human embryo hepatocyte line L02.
They established L02/core cell line that stably expressing HCV-core protein, and demonstrated that HCV core protein activated OAS gene promoter specifically and effectively. Utilization of OAS gene promoter would be an ideal strategy for developing HCV-specific gene therapy.
Reference:
Wang Y, Mao SS, He QQ, Zi Y, Wen JF, Feng DY. Specific activation of 2"-5"oligoadenylate synthetase gene promoter by hepatitis C virus-core protein: A potential for developing hepatitis C virus targeting gene therapy. World J Gastroenterol 2009; 15(25): 3178-3182 http://www.wjgnet.com/1007-9327/15/3178.asp
Correspondence to:
De-Yun Feng, Department of Pathology, College of Basic Medical Sciences, Central South University, Changsha 410078, Hunan Province, China.
Lin Tian
World Journal of Gastroenterology